Danaher Corporation (NYSE:DHR) Position Cut by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC decreased its position in shares of Danaher Corporation (NYSE:DHR) by 8.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,906 shares of the conglomerate’s stock after selling 7,443 shares during the quarter. Danaher comprises about 1.0% of Motley Fool Wealth Management LLC’s investment portfolio, making the stock its 27th largest holding. Motley Fool Wealth Management LLC’s holdings in Danaher were worth $16,586,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. FAS Wealth Partners Inc. grew its stake in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock worth $2,203,000 after purchasing an additional 1,639 shares in the last quarter. MGO One Seven LLC lifted its holdings in Danaher by 485.7% in the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. bought a new position in Danaher in the 1st quarter valued at about $539,000. Horizon Financial Services LLC increased its stake in Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after buying an additional 8,160 shares during the period. Finally, EFG Asset Management Americas Corp. raised its position in shares of Danaher by 13.1% during the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate’s stock worth $7,396,000 after buying an additional 4,191 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.1%

Shares of Danaher stock opened at $200.70 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The stock has a 50-day moving average price of $198.46 and a 200 day moving average price of $200.62. The company has a market cap of $143.71 billion, a P/E ratio of 42.70, a P/E/G ratio of 2.80 and a beta of 0.73.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The firm’s revenue was up 3.4% on a year-over-year basis. As a group, analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DHR. Jefferies Financial Group decreased their price objective on shares of Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a report on Tuesday, April 22nd. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research note on Friday, July 11th. JPMorgan Chase & Co. dropped their price objective on Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 22nd. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.